Saltar al contenido
Merck

SML2591

Sigma-Aldrich

SCH-39166 hydrobromide

≥98% (HPLC)

Sinónimos:

(-)-trans-6,7,7a,8,9,13b-Hexahydro-3-chloro-2-hydroxy-N-methyl- 5H-benzo[d]naptho-(2,1-b)azepine hydrobromide, (6aS,13bR)-11-Chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5H-benzo[d]naphth[2,1-b]azepin-12-ol hydrobromide, (6aS-trans)-11-Chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-5H-Benzo[d]naphth[2,1-b]azepin-12-ol hydrobromide, Ecopipam hydrobromide, PSYRX 101 hydrobromide, PSYRX-101 hydrobromide, PSYRX101 hydrobromide, SCH 39166 hydrobromide, SCH39166 hydrobromide

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C19H20ClNO·HBr
Número de CAS:
Peso molecular:
394.73
Número MDL:
Código UNSPSC:
12352200
NACRES:
NA.77

Análisis

≥98% (HPLC)

formulario

powder

condiciones de almacenamiento

desiccated

color

white to beige

solubilidad

DMSO: 2 mg/mL, clear

temp. de almacenamiento

2-8°C

Acciones bioquímicas o fisiológicas

SCH-39166 (ecopipam) is a high-affinity D1/D5 subtype-selective dopamine receptor antagonist (Ki = 1.2 nM/D1, 2.0 nM/D5, 980 nM/D2, 5.52 μM/D4, 80 nM/5-HT, 731 nM/α2a). SCH-39166 is widely employed both in cultures and in animal studies in vivo.

Pictogramas

Exclamation mark

Palabra de señalización

Warning

Frases de peligro

Clasificaciones de peligro

STOT SE 3

Órganos de actuación

Central nervous system

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Martin Clark et al.
Frontiers in cellular neuroscience, 12, 260-260 (2018-09-07)
The ventral pallidum (VP) is crucially involved in reward processing. Dopaminergic afferents reach the VP from the ventral tegmental area (VTA). Recent in vivo studies suggest dopamine application increase the firing in the VP. However, little is known about the
Yunjin Lee et al.
Experimental neurobiology, 27(6), 539-549 (2019-01-15)
Autism spectrum disorder (ASD) is a heterogeneous group of neurobehavioral disorders characterized by the two core domains of behavioral deficits, including sociability deficits and stereotyped repetitive behaviors. It is not clear whether the core symptoms of ASD are produced by
Takeshi Enomoto et al.
Behavioral neuroscience, 132(6), 526-535 (2018-10-10)
Effort-based decision-making paradigms have recently been used to measure motivation in healthy subjects and patients with neuropsychiatric disorders. In the present study, we developed a novel effort-discounting paradigm using a touch-panel system in common marmosets. Marmosets were trained to choose
Nao Matsuyama et al.
Respiratory research, 19(1), 53-53 (2018-04-03)
Dopamine receptors comprise two subgroups, Gs protein-coupled “D1-like” receptors (D1, D5) and Gicoupled “D2-like” receptors (D2, D3, D4). In airways, both dopamine D1 and D2 receptors are expressed on airway smooth muscle and regulate airway smooth muscle force. However, functional
M A Tice et al.
Pharmacology, biochemistry, and behavior, 49(3), 567-571 (1994-11-01)
Characterization studies were conducted on the five cloned dopamine receptor subtypes (D1-D5) using the novel D1-selective antagonist, SCH 39166, as well as other related benzazepines and dopaminergic agents. The results demonstrate that SCH 39166 exhibits saturable, high-affinity binding to the

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico